Extended Research Article
Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial
Dena R Howard
,
Talha Munir
,
Lucy McParland
,
Andy C Rawstron
,
Anna Chalmers
,
Walter M Gregory
et al.
-
Journal:
Health Technology Assessment Volume: 21, Issue: 28
-
Published:
23 May 2017